期刊
CELLS
卷 10, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/cells10061533
关键词
sarcoma; gastrointestinal stromal tumor; fibroblast growth factor receptors; tyrosine kinase inhibitors
类别
资金
- Royal Marsden/Institute of Cancer Research National Institute for Health Research Biomedical Research Centre
FGFR pathway alterations have been identified in various sarcoma subtypes, suggesting potential therapeutic targets. However, clinical trials have shown low efficacy of selective FGFR inhibitors, highlighting the need for further research to identify patients who will benefit most from this targeted therapy.
Sarcomas are a heterogeneous group of rare malignancies originating from mesenchymal tissues with limited therapeutic options. Recently, alterations in components of the fibroblast growth factor receptor (FGFR) signaling pathway have been identified in a range of different sarcoma subtypes, most notably gastrointestinal stromal tumors, rhabdomyosarcomas, and liposarcomas. These alterations include genetic events such as translocations, mutations, and amplifications as well as transcriptional overexpression. Targeting FGFR has therefore been proposed as a novel potential therapeutic approach, also in light of the clinical activity shown by multi-target tyrosine kinase inhibitors in specific subtypes of sarcomas. Despite promising preclinical evidence, thus far, clinical trials have enrolled very few sarcoma patients and the efficacy of selective FGFR inhibitors appears relatively low. Here, we review the known alterations of the FGFR pathway in sarcoma patients as well as the preclinical and clinical evidence for the use of FGFR inhibitors in these diseases. Finally, we discuss the possible reasons behind the current clinical data and highlight the need for biomarker stratification to select patients more likely to benefit from FGFR targeted therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据